Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells
Summary
USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.
What changed
USPTO granted patent protection for a novel method of producing a pharmaceutical agent targeting cervical cancer cells. The method involves producing metal powder via electric explosion of low-carbon steel wire under controlled conditions, followed by passivation and mixing with cell culture medium. The resulting liquid phase is used as the therapeutic agent.
For pharmaceutical manufacturers and oncology researchers, this patent establishes intellectual property protection in the cervical cancer treatment space. Parties developing similar cancer cell inhibition methods should conduct freedom-to-operate analyses to avoid infringement. The patent covers applications in experimental oncology and may affect competitive dynamics in cancer therapeutic development.
What to do next
- Monitor patent portfolio for freedom-to-operate considerations
- Review patent claims for potential licensing opportunities
- Consult IP counsel regarding competitive implications
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of obtaining a pharmaceutical agent used for inhibiting the proliferation of tumor cells
Grant US12599626B2 Kind: B2 Apr 14, 2026
Assignee
LIMITED LIABILITY COMPANY “LABORATORY OF INNOVATIVE TECHNOLOGIES”
Inventors
Lyudmila Nikolaevna Shiyan, Galina Leonidovna Lobanova, Alexey Vitalievich Pustovalov, Mikhail Alexandrovich Buldakov, Tatiana Alexandrovna Yurmazova, Fedor Zotov, Dmitry Igorevich Shvartsman, Anastasia Alekseevna Evtina
Abstract
The given invention is related to the field of medicine, namely to experimental research in oncology, and can be used to obtain a pharmaceutical agent for inhibiting the proliferation of HeLa cervical cancer cells. It entails the use of a metal powder obtained in a gaseous medium by means of an electric explosion of a wire made of low-carbon steel carried out with a specific energy of 7-18 KJ/g and a pulse duration of 1.2-2 μs. The explosion is carried out inside a reactor that is pre-evacuated to a residual pressure of 10−2 Pa. and then filled with carbon monoxide to a pressure of 105 Pa at a gas circulation rate flow of 10 m/s. The products of the explosion deposited in a hopper are passivated in air for at least 48 hours. The resulting powder is extracted and mixed with a solution of the RPMI-1640 nutrient medium with L-glutamine, a pH of 7.2, in the proportion of the mass of the powder to the volume of the specified solution from 1:10 to 2.7:10. The solution is then centrifuged until the phases are separated. The liquid phase is decanted and used as a pharmaceutical agent. The purpose of the given invention is to expand the arsenal of tools for inhibiting the proliferation of tumor cells.
CPC Classifications
A61K 33/26 A61P 35/00 B22F 1/052 B22F 1/056 B22F 1/147 B22F 9/14 B22F 2301/35 B22F 2304/054 B22F 2304/10 B22F 2998/10 B22F 1/054 B22F 2999/00 B82B 3/00
Filing Date
2022-01-10
Application No.
18259175
Claims
1
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.